Inhibition of estrone sulfate-induced uterine growth by potent nonestrogenic steroidal inhibitors of steroid sulfatase

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6442-6446

  Ciobanu, Liviu C ^a   Luu The, Van ^a   Martel, Céline ^a   Labrie, Fernand ^a   Poirier, Donald ^a,b  

^a UNIVERSITY OF QUEBEC   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXY 3 SULFAMOYLOXY 17ALPHA BENZYLESTRA 1,3,5(10) TRIEN 17BETA OL; 3 SULFAMOYLOXY 17 ALPHA 4 TERT BUTYLBENZYL 1,3,5(10) ESTRATRIEN 17BETA OL DERIVATIVE; ANTIESTROGEN; ESTRONE; ESTRONE 3 O SULFAMATE; ESTRONE SULFATE; HYDROXYSTEROID DEHYDROGENASE; STERYL SULFATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; DRUG SYNTHESIS; ENZYME INHIBITION; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; UTERUS GROWTH;

ANIMALS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTRONE; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; STERYL-SULFATASE; UTERUS;

EID: 0141919555     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Pasqualini, J. R. Role, control and expression of estrone sulfatase and 17β-hydroxysteroid dehydrogenase activities in human breast cancer. Zentralblatt für Gynäkologie, 119: 48-53, 1997.
2. Wakeling, A. E. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocrine-related Cancer, 7: 17-28, 2000.
3. von Angerer, E. The estrogen receptor as a target for rational drug design. Molecular Biology Intelligence Unit. Austin, TX: R. G. Landes Company, 1995.
4. Smith, H. J., Nicholls, P. J., Simons, C., and Le Lain, R. Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers. Exp. Opin. Ther. Patents, 11: 789-824, 2001.
5. Dowsett, M. Aromatase inhibition: the outcome of 20 years of drug development. In: W. R. Miller and R. J. Santen (eds.), Aromatase Inhibition and Breast Cancer, pp. 3-15. New York: Marcel Dekker, 2001.
6. Lombardi, P. The irreversible inhibition of aromatase (oestrogen synthetase) by steroidal compounds. Curr. Pharm. Des., 1: 23-50, 1995.
7. Brodie, A. M. H., and Njar, V. C. O. Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. J. Steroid Biochem. Mol. Biol., 66: 1-10, 1998.
8. Penning, T. M. 17β-Hydroxysteroid dehydrogenase: inhibitors and inhibitor design. Endocrine-related Cancer, 3: 41-56, 1996.
9. Poirier, D. Inhibitors of 17β-hydroxysteroid dehydrogenases. Curr. Med. Chem., 10: 453-477, 2003.
10. Poirier, D., Ciobanu, L. C., and Maltais, R. Steroid sulfatase inhibitors. Exp. Opin. Ther. Patents, 9: 1083-1099, 1999.
11. Ahmed, S., Owen, C. P., James, K., Sampson, L., and Patel, C. K. Review of estrone sulfatase and its inhibitors. An important new target against hormone dependent breast cancer. Curr. Med. Chem., 9: 263-273, 2002.
12. Nussbaumer, P., and Billich, A. Steroid sulfatase inhibitors. Exp. Opin. Ther. Patents, 13: 605-625, 2003.
13. Santen, R. J., and Harvey, H. A. Use of aromatase inhibitors in breast carcinoma. Endocrine-related Cancer, 6: 75-92, 1999.
14. Goss, P. E., and Strasser, K. Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin. Oncol., 19: 881-894, 2001.
15. Hamilton, A., and Piccart, M. The third generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second line hormonal treatment of advanced breast cancer. Ann. Oncol., 10: 377-384, 1999.
16. Brueggemeier, R. W. Overview of the pharmacology of the aromatase inactivator exemestane. Breast Cancer Res. Treat., 74: 177-185, 2002.
17. Adams, J. B. Control of secretion and the function of C19-delta 5-steroids of the human adrenal gland. Mol. Cell. Endocrinol., 41: 1-17, 1985.
18. Poulin, R., and Labrie, F. Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res., 46: 4933-4937, 1986.
19. Simard, J., Vincent, A., Duchesne, R., and Labrie, F. Full oestrogenic activity of C19-delta 5 adrenal steroids in rat pituitary lactotrophs and somatotrophs. Mol. Cell. Endocrinol., 55: 233-242, 1988.
20. Hawkins, R., Thomson, M. L., and Killen, E. Oestrone sulphate, adipose tissue, and breast cancer. Breast Cancer Res. Treat., 6: 75-87, 1985.
21. Pasqualini, J. R., Nguyen, B. L., and Vella, C. Importance of estrogen sulfates in breast cancer. J. Steroid Biochem., 34: 155-163, 1989.
22. Labrie, F., Luu-The, V., Lin, S. X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., and Bélanger, A. Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 25: 1-16, 2000.
23. Santner, S. J., Feil, P. D., and Santen, R. J. In situ estrogen production via estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocrinol. Metab., 59: 29-33, 1984.
24. Pasqualini, J. R., Chetrite, G., Blacker, C., Feinstein, M. C., Delalonde, L., Talbi, M., and Maloche, C. Concentration of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab., 81: 1460-1464, 1996.
25. Howarth, N. M., Purohit, A., Reed, M. J., and Potter, B. V. L. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem., 37: 219-221, 1994.
26. Purohit, A., Williams, G. J., Roberts, C. J., Potter, B. V. L., and Reed, M. J. Inactivation of steroid sulfatase by an active-site directed inhibitor, estrone-3-O-sulphamate. Biochemistry, 34: 11508-11514, 1995.
27. Elger, W., Schwarz, S., Hedden, A., Reddersen, G., and Schneider, B. Sulfamates of various estrogens-prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Mol. Biol., 55: 396-403, 1995.
28. Purohit, A., Vernon, K. A., Woo, L. W. L., Hejaz, H. A. M., Potter, B. V. L., and Reed, M. J. The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulfatase inhibitors with reduced oestrogenicity. J. Steroid Biochem. Mol. Biol., 64: 269-275, 1998.
29. Merriam, G. R., MacLusky, N. J., Picard, M. K., and Naftolin, F. Comparative properties of the catechol estrogens, I: methylation by catechol-O-methyltransferase and binding to cytosol estrogen receptors. Steroids, 36: 1-11, 1980.
30. Seegers, J. C., Aveling, M. L., van Aswegen, C. H., Cross, M., Koch, F., and Joubert, W. S. The cytotoxic effects of estradiol-17β, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. J. Steroid Biochem., 32: 797-809, 1989.
31. LaVallee, T. M., Zhan, X. H., Herbstritt, C. J., Kough, E. C., Green, S. J., and Pribluda, V. S. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors α and β. Cancer Res., 62: 3691-3697, 2002.
32. Huang, P., Feng, L., Oldham, E. A., Keating, M. J., and Plunkett, W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature (Lond.), 407: 390-395, 2000.
33. Fotsis, T., Zhang, Y., Pepper, M. S., Adlercreutz, H., Montesano, R., Nawroth, P. P., and Schweigerer, L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature (Lond.), 368: 237-239, 1994.
34. Klauber, N., Parangi, S., Flynn, E., Hamel, E., and D'Amato, R. J. Inhibition of angiogenesis and breast cancer in mice by microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res., 57: 81-86, 1997.
35. Tsutsui, T., Tamura, Y., Hagiwara, M., Miyachi, T., Hikiba, H., Kubo, C., and Barrett, J. C. Induction of mammalian cell transformation and genotoxicity by 2-methoxyestradiol, an endogenous metabolite of estrogen. Carcinogenesis (Lond.), 21: 735-740, 2000.
36. Boivin, R. P., Luu-The, V., Lachance, R., Labrie, F., and Poirier, D. Structure-activity relationships of 17alpha-derivatives of estradiol as inhibitors, of steroid sulfatase. J. Med. Chem., 43: 4465-4478, 2000.
37. Ciobanu, L. C., Boivin, R. P., Luu-The, V., Labrie, F., and Poirier, D. Potent inhibition of steroid sulfatase activity by 3-O-sulfamate-17α -(benzyl of 4′-t-butylbenzyl)-estra-1, 3, 5(10)-trienes: combination of two substituents at positions C3 and C17α of estradiol. J. Med. Chem., 42: 2280-2286, 1999.
38. Ciobanu, L. C., Boivin, R. P., Luu-The, V., and Poirier, D. 3β-Sulfamate derivatives of C19 and C21 steroids bearing a t-butylbenzyl or a benzyl group: synthesis and evaluation as non-estrogenic and non-androgenic steroid sulfatase inhibitors. J. Enz. Inh. Med. Chem., 18: 15-26, 2003.
39. Nambara, T., Honma, S., and Akiyama, S. Studies on steroid conjugates. III. New syntheses of 2-methoxyestrogens. Chem. Pharm. Bull., 18: 474-480, 1970.
40. Peterson, E. M., Brownell, J., and Vince, R. Synthesis and biological evaluation of 5′-sulfamoylated purinyl carbocyclic nucleosides. J. Med. Chem., 35: 3991-4000, 1992.
41. Kramer, C. Y. Extension of multiple range tests to group means with unique numbers of replications. Biometrics, 12: 307-310, 1956.
42. Santner, S. J., and Santen, R. J. Inhibition of estrone sulfatase and 17β-hydroxysteroid dehydrogenase by antiestrogens. J. Steroid Biochem. Mol. Biol., 45: 383-390, 1993.
43. Cushman, M., He, H. M., Katzenellenbogen, J. A., Varma, R. K., Hamel, E., Lin, C. M., Ram, S., and Sachdeva, Y. P. Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth. J. Med. Chem., 40: 2323-2334, 1997.